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Abstract
Prophylactic administration of CpG oligodeoxynucleotides (CpG ODNs) is known to confer protection against lethal sepsis
caused by Burkholderia pseudomallei in the mouse model. The mechanisms whereby CpG regulates the innate immune
response to provide protection against B. pseudomallei, however, are poorly characterized. In the present study, we
demonstrate that intranasal treatment of mice with Class C CpG, results in recruitment of inflammatory monocytes and
neutrophils to the lung at 48 h post-treatment. Mice infected with B. pseudomallei 48 h post-CpG treatment had reduced
organ bacterial load and significantly altered cytokine and chemokine profiles concomitant with protection as compared to
control animals. CpG administration reduced the robust production of chemokines and pro-inflammatory cytokines in
blood, lung and spleen, observed following infection of non-treated animals. Death of control animals coincided with the
time of peak cytokine production (day 1–3), while a moderate; sustained cytokine production in CpG-treated animals was
associated with survival. In general, CpG treatment resulted in diminished expression of cytokines and chemokines post-
infection, though IL-12p40 was released in larger quantities in CpG treated animals. In contrast to CpG-treated animals, the
lungs of infected control animals were infiltrated with leukocytes, especially neutrophils, and large numbers of necrotic
lesions were observed in lung sections. Therapeutic treatment of B. pseudomallei-infected animals with CpG at 24 h post-
infection did not impact survival compared to control animals. In summary, protection of CpG-treated animals was
associated with recruitment of inflammatory monocytes and neutrophils into the lungs prior to infection. These responses
correspond with early control of bacterial growth, a dampened inflammatory cytokine/chemokine response, reduced lung
pathology, and greatly increased survival. In contrast, a delay in recruitment of inflammatory cell populations, despite a
robust production of pro-inflammatory cytokines, was associated with poorly controlled bacterial growth, severe lung
pathology, and death of control animals.
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Introduction
In the absence of a licensed vaccine, Burkholderia pseudomallei, the
etiologic agent for melioidosis, presents a significant threat as a
potential agent for bioterrorism due to its high rate of infectivity if
acquired via the respiratory tract, combined with resistance to
many commonly used antibiotics [1]. This intracellular Gram
negative bacteria is endemic throughout Northern Australia and
parts of Southeast Asia, where as much as 20% of septicemia is
attributed to melioidosis [1,2]. Previous studies have shown that
immunization with oligodeoxynucleotides containing unmethy-
lated deoxycytosine-deoxyguanosine motifs (type B) can protect
mice from low doses of aerosol or intraperitoneally administered
Burkholderia infection [3,4,5]. CpG ODNs have also been
administered alone as a pretreatment to effectively protect mice
from infection by different bacterial pathogens [6].
CpGODNsare recognized byToll-like receptor9(TLR9) andare
potent inducers of the innate immune system, mimicking the effects of
bacterial DNA. Three classes of CpG ODNs that act as TLR9
agonists have been described with different abilities to activate
immune system. Class A induce very high levels of IFN-a produced
by plasmocytoid dendritic cells, class B induce strong B and NK cell
activation and class C combine most efficiently the properties of both
the A and B classes [7,8,9,10], and induce preferential development
and differentiation of T helper 1 (Th1) cells [10,11]. The CpG ODNs
can potentially be used in broad applications as a vaccine adjuvant, a
stand-alone therapy, or in combination with other therapies in
cancer, infectious diseases, asthma and allergy [12,13,14]. As such,
the use of CpG ODNs may be critical in developing an effective
immune response to B. pseudomallei [2,9,11,15].
CpG type B pre-treatment resulted in elevated serum levels of
IL-12p70 and IFN-c and decreased bacteremia in BALB/c mice
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protective against aerosol exposure to the related pathogen B.
mallei, the etiologic agent of glanders [4]. Additionally, CpG
administration enhanced digestion of apoptotic neutrophils by
macrophage populations, accompanied with an increase in the
level of TNF-a [16]. Such a mechanism could limit dissemination
and replication of B. pseudomallei by promoting antibacterial and
phagocytic activity by these innate immune populations to limit
bacterial numbers and inflammation. In an acute lung injury
murine model, administration of CpG reduced neutrophil
mobilization to alveolar spaces as well as the pro-inflammatory
cytokine response [17].
Infections of both humans and mice have been reported to have
elevated levels of a number of pro-inflammatory cytokines and
mediators following B. pseudomallei infection [5,18,19,20]. While a
cytokine response may assist recovery, as evidenced by the
protection of animals administered IFN-c, the hyper-responsive
production of pro-inflammatory cytokines may induce immuno-
pathology [20,21,22,23]. Because the development of the acute
form of melioidosis in BALB/c mice seems to be associated with
an increase in inflammation [24], the broad analysis of
chemokines and cytokines would be a useful platform for
investigating protective role of CpG ODN and could further
identify candidate cells of innate immune system that contribute to
protective or pathological responses.
As this study demonstrates, early activation of innate immunity
via a TLR9 agonist (CpG ODN Type C) alters the cytokine
profiles and shifts the innate host defense response to B. pseudomallei
in a protective manner. Activation of the innate immune system
prior to infection to reduce the severity of the disease in susceptible
populations could provide a window of opportunity for adequate
treatment, which in the case of melioidosis could be critical. Our
results significantly advance the understanding regarding innate
immunity in both protection and immunopathogenesis following
B. pseudomallei infection, and describe the protective responses due
to CpG ODN treatment applicable to development of medical
countermeasures for melioidosis.
Results
Effects of CpG ODN treatment on survival
BALB/c mice are highly susceptible to B. pseudomallei infection
and provide an excellent model for acute melioidosis. A previous
study demonstrates that administration of CpG ODN type B at
48 h before challenge is optimal for protection from B. pseudomallei
[5]. Therefore, eight-week old female BALB/c mice were given
20 mg of CpG ODN 2137, type C i.n. 48 h prior to intranasal
challenge with B. pseudomallei K96243 (2–4 LD50). For comparison
between type C and type B CpG ODN, we treated an additional
group of BALB/c mice with type B CpG ODN 2138. We
observed that the non-treated control mice became sick within
48 h post-challenge as indicated by non-specific signs such as
piloerection and hypoactivity with trembling. As expected, the
majority of deaths in the control group occurred within 3 to 6 days
post-infection (Figure 1). Our data demonstrated clearly that
pretreatment with both CpG ODN type B or C significantly
prolonged the survival time in B. pseudomallei infected animals.
Administration of CpG ODN type B or C 48 h prior to i.n.
infection with B. pseudomallei (2 LD50) resulted in 80% to 100%
protection in all experiments (Figure 1A). The studies using higher
infectious doses, and for the remainder of our studies, were
performed with CpG ODN 2137, type C which has been shown to
be optimal for augmenting broader immune responses [10]. A
lower degree of protection (70% and 50%) was still observed when
higher challenge doses (3LD50 or 4 LD50) were given to the mice
(Figures 1B and C). In all experiments, days 2 and 3 post infection
was a consistent turning point for disease progression in susceptible
BALB/c mice and suggested that early proper activation of innate
immunity can be extremely important in protection against
intracellular bacteria in the acute form of disease. In contrast,
post-infection with CpG type C treatment was not protective and
most animals from both treated and control groups died between
days 2 and 5 (Fig. 1D).
Effects of CpG ODN on bacterial load and the course of
infection
To test the effect of CpG ODN 2395 (C-class), we examined the
kinetics of bacterial clearance or colonization in BALB/c mice
infected i.n. with B. pseudomallei K96243 (dose 2LD50). We isolated
residual bacteria from two animals euthanized at each time point
from control and CpG treated group on days 1, 2, 3, 6, and 13
post-infection and at the end of the study. Most untreated control
animals died between day 3 to 6 and CFU determination data
after day 6 was not available from this control group of animals.
Bacteria were detected in lungs and spleens 24 h post infection
in both groups of animals (Figure 2). However, animals treated
with CpG had reduced bacterial growth in lungs compared to the
control group (Figure 2A). On day 1 post-infection, only 36 CFUs
were found per mg tissue in the animals treated with CpG and
number of bacteria had reached the highest level of 456 CFUs/
mg by day 3. By day 6 post-infection, the bacterial load was
substantially reduced as compared to day 1 and only few CFUs
were detected in lungs per mg of tissue. A low level of bacteria
(1.0–22 CFUs/mg) in the lungs of CpG- treated animals was
maintained during the remaining course of infection (Figure 2A).
Control animals displayed higher levels of bacteria in lungs
starting at 24 h post-infection as compared to CpG treated mice.
By day 6, the mean number of bacteria found in lungs was
1.62610
5 CFUs/mg of tissue, and most of control animals died
around that day. The surviving CpG treated animals also
controlled bacterial growth in the spleen better than untreated
controls during the first three days post-infection (Figure 2B).
However, though CpG-treated animals survived and had low
organ bacterial burdens at the time that most control animals died,
by day 6, bacteria increased in spleen in the CpG treated mice and
continued to increase by the end of the study (3 weeks).
Histopathology
Lungs from all infected animals at days 1–6 post infection
showed multifocal abscess formation dominated by neutrophils
with few admixed macrophages. In CpG treated animals, lungs
had fewer and smaller lesions than did control animals (Table 1)
(Figure 3). Lesion numbers for both groups peaked at day 2–3. At
all-time points, control animals had 3–15 times more lesions in
lung sections examined than did CpG treated animals. For the
CpG treated animals, beginning on day 6 post infection, lesions
were difficult to find and relatively small, occupying only 1–2
alveolar spaces. By contrast, in control animals, severe lesions were
still seen at day 6, just prior to death. Necrosis was noted in
association with neutrophil aggregates in six of eight control
animals at days 1–6, whereas necrosis was rarely seen in CpG
treated animals (one of eight animals at days 1–6).
Effect of CpG ODN on recruitment of inflammatory cell
populations
In a separate study, groups of mice were either mock (PBS) or
CpG treated (i.n.) and sacrificed at time 0 (time of infection and
CpG-Mediated Protection during Melioidosis
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B. pseudomallei. Peripheral blood and lung leukocytes were isolated
and flow cytometric analysis was performed to quantitate
inflammatory cell populations. Assessment was done based on
number of cells in equal volume of sample (blood, total lung
homogenate) from each animal. The cell populations were
identified based on surface phenotype markers; F4/80
+Gr1
+
(inflammatory monocytes), F4/80
2CD11c
2CD11b
+Gr1
+ (neutro-
phils) and F4/80
+Gr1
2 (macrophages) (Figure 4A). We observed a
robust increase in inflammatory monocytes and neutrophils in
both the blood and lungs by 48 hours after CpG administration
and prior to infection (Figure 4B and C). Animals which received
20 mg CpG ODN intranasally had 1.5 times higher level of
inflammatory monocytes in blood and almost 13 times higher level
of inflammatory monocytes in lungs prior to infection (time 0) as
compared to control mice. Similarly, CpG ODN treatment
resulted in significantly increased numbers of neutrophils in the
blood and lungs (Figure 4B and C). The numbers of neutrophils
observed 48 h after CpG administration, but prior to infection,
was 3.9 times higher in blood and 5.8 times higher in lungs as
compared to controls. These significant differences in numbers of
inflammatory cell populations in blood and lungs between CpG
treated and not treated groups were no longer observed by 48 h
post infection. In contrast, neutrophils were abundant in the lung
of both CpG- and non-treated groups by 48 h post-infection while
monocyte numbers were not different from control animal
baseline values (Figure 4B and C). Our results indicate that early
activation of innate immunity by CpG ODN allowed for effective
control of this invading pathogen at the site of infection and
contributed to the survival of CpG treated animals.
Effect of CpG ODN on chemokine/cytokine profile
To determine the immune responses associated with protection
generated by CpG administration against the acute form of disease
caused by B. pseudomallei, we evaluated chemokines/cytokines
produced post infection in blood, lung and spleen. The cytokine
response in the first three days post infection corresponded with
detrimental disease progression as most control animals died
between days 3 and 6. Without the CpG pretreatment, B.
pseudomallei infection was associated with robust, increased levels of
chemokines and cytokines in blood, lungs and spleens, peaking
within three days post infection (Figures 5, 6, and 7, Figure S1). All
measured chemokines were strongly up-regulated in the plasma of
control animals, with the amount of MCP-1 at days 1 and 3, MIP-
1b and RANTES at day 2, being statistically different as compared
to that of CpG treated mice (Figure 5). Starting at day 1 post
infection, control animals also had higher levels of several
cytokines, including IL-1a, IL-1b, IL-6, IL-12p70, and IFN-c in
plasma, additionally IL-17 and TNF-a and chemokines (KC,
MCP-1, MIP-1a) were elevated in lungs (Figures 6 and 7). G-CSF
Figure 1. Survival curves of B. pseudomallei strain K96243. Percentage of survival of BALB/c mice challenged intranasally with 2 LD50 (panel A),
3L D 50 (panel B), 4 LD50 (panel C) of B. pseudomallei strain K96243 (n=10). CpG ODN 1826 type B or ODN 2395, type C was administrated 48 h prior to
infection at 20 mg/mouse in 50 ml of water. Control animals received non-CpG ODN, for type B ODN 2138 and ODN 2137 for type C. The infection of B.
pseudomallei resulted in 90–100% death in non-treated animals. Survival of CpG treated animals ranged from 80–90% for 2 LD50 to 50% for 4 LD50.
Post-challenge (1 h) administration of CpG ODN type C did not protect animals and both control and CpG treated animals died between days 2 and 5
(panel D). Kaplan-Meier analysis followed by log rank test was used to determine statistical differences.
doi:10.1371/journal.pone.0034176.g001
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spleens of control animals throughout the first 3 days post infection
with consistent statistical differences in lungs between control and
CpG treated mice (Figures 6 and 7, Figure S1). While the level of
G-CSF was abundant in control animals, the IL-12p40 was the
only cytokine consistently elevated in CpG treated mice as
compared to controls. No significant differences due to treatment
were noted for several other molecules (IL-2, IL-3, IL-4, IL-5, IL-
9, IL-10, IL-13, GM-CSF, MIP-1b, or RANTES) measured via
the 23-plex platform. Statistical differences were detected only on
day 1 post infection in lungs and in plasma at day 6. The cytokines
previously shown to be important in protection against B.
pseudomallei, such as TNF-a, IFN-c and IL-12p70, were detected
at moderate levels in CpG treated BALB/c mice throughout the
course of infection (Figures 6 and 7). Most of cytokines and
chemokines measured in the lungs were detected in much higher
level in control animals. We observed a strong induction (burst) of
cytokines and chemokines in lungs of control animals at day 1 with
declining trend during the next three days, although the quantities
were still higher when compared to CpG treated animals. The
significant differences were seen in IL-1b (day 1), IL-6 (days 2 and
3), G-CSF (days 1, 2 and 3), TNF-a (day 1) and MCP-1 (day 3). By
day 6, production of cytokines dropped significantly and was
similar in both groups.
Discussion
The pathogenesis of melioidosis and the accompanying host
immune response varies widely based on host susceptibility and
route of delivery. Studies of Burkholderia infection in murine models
have demonstrated a distinct susceptibility of BALB/c mice
compared to C57BL/6 mice [25,26]. Because BALB/c mice are
very susceptible to both intravenous and intranasal B. pseudomallei
infections, this mouse strain was chosen to investigate in detail the
innate immune responses generated by unmethylated CpG
oligodeoxynucleotides. The CpG ODNs are known to be potent
immunomodulators and induce highly effective protective immu-
nity in a number of infectious diseases including tularemia [6],
listeriosis [27], Leishmania [28] and B. mallei or B. pseudomallei
infections [4,5,6,9,15]. However, the positive immunostimulatory
effect of CpG can be diminished in the case of infection with
highly virulent bacterial strains which actively impair the host
immune response such as Francisella tularensis Schu S4 strain [3].
Consistent with these observations, we showed that pretreatment
with CpG ODN types B or C administered i.n. significantly
prolonged the survival of B. pseudomallei infected BALB/c mice.
Figure 2. Bacterial recovery from infected organs. Bacterial
burden in lungs (A) and spleens (B) were determined in two mice per
time point. Mice received CpG ODN, type C 48 h prior challenge with B.
pseudomallei. Values are expressed as log10 CFU per mg of tissue and
presented as means 6 SEM. Statistical differences were determined
using two-tailed Student t test. *p,0.05, ***p,0.001.
doi:10.1371/journal.pone.0034176.g002
Table 1. Summary of lesions observed and their characteristics.
a
Treatment Day post infection Average # of lesions per section Lesion size range
CpG 1 0.3 4 to 10 alveoli
CpG 2 0.8 2 to 18 alveoli
CpG 3 4.3 2 to 20 alveoli
CpG 6 0.3 0 to 1 alveolus
CpG 13 0.0 No lesions seen
CpG 15 1.0 0 to 2 alveoli
CpG 25 1.0 1 to 2 alveoli
Control 1 1.1 5 to 25 alveoli
Control 2 12.5 2 to 30 alveoli
Control 3 3.8 1 to 40 alveoli
Control 6 2.00 1 to 40 alveoli
aLung samples from two animals from each group and time point were examined after routine H&E staining. Lesion count is estimated as the average number of lesions
per lung section for the two animals. Lesion size is reported as the number of alveoli filled by neutrophils.
doi:10.1371/journal.pone.0034176.t001
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100% at 2 LD50 to 50% with 4 LD50 (Figure 1). In all experiments,
day 3 post infection was shown to be a critical point and most
deaths in the control group occurred within days 3 to 6 post
infection. Our data suggested that in the case of acute pulmonary
melioidosis, the initial responses generated by innate immunity are
extremely important for protection.
The kinetics of bacterial clearance or colonization in lungs and
spleens were determined at 6 different time points after challenge
to investigate contributing factors to protection generated by CpG
ODN type C. Control BALB/c mice had an overwhelming
bacterial load in both the lungs and spleen (Figure 2). Previous
studies showed that BALB/c mice infected intravenously with B.
pseudomallei developed elevated bacterial loads in the lung and
spleen with considerably fewer bacteria in the liver [25]. The
difference in bacterial numbers between control and CpG treated
animals in our studies was observed from day 1 and continued
until day 6 post infection, when most control animals died. Our
observations are in agreement with experiments with BALB/c
mice pretreated with CpG ODN, type B and i.p. infected with B.
pseudomallei [5]. Bacterial levels detected in blood were low and
found in small proportion of CpG pre-treated mice. CpG, type C
pre-treated mice in our study maintained low level of bacteria in
lungs with an increased observed only at day 3 post infection. After
this time point, bacteria in CpG pre-treated mice were well
controlled in lungs till end of the study. The organism was also
detected in low numbers very early (day 1 post infection) in the
spleen in all animals indicating the early spread of bacteria into the
blood stream. Colonization of the bacteria in the spleen observed
during late course of infection indicate that animals did not
develop efficient clearance mechanism in that organ and bacteria
were able to grow rapidly later, reaching elevated numbers at the
end of the study (day 21). In support of the greater survival that we
and others have observed, here it was demonstrated that CpG pre-
treatment of BALB/c mice led to recruitment of innate immune
cell populations that promotes clearance of the bacteria, at the
primary site of infection (lung). The non-activated state of the
innate immune system in the control animals likely allowed the
rapid growth of B. pseudomallei in lungs, leading to a subsequent
robust activation of pro-inflammatory responses which were not
adequate for clearance of the bacteria and yet had a negative
outcome.
Control of bacterial growth in our studies correlated with the
early recruitment of large numbers of inflammatory monocytes
and neutrophils to the site of infection (lungs) in CpG treated
animals. We found a significantly higher number of inflammatory
monocytes and neutrophils in blood and lungs in animals
pretreated with CpG ODN prior to infection. Neutrophils and
monocytes are a key component of the innate immunity and are
important for protection against pathogens. They have a critical
early role in resistance, both by direct antimicrobial activity
(release of antibacterial molecules and proteinases) and by
production of immunoregulatory chemokines and cytokines that
recruit and activate other immune cells. Early recruitment of
monocytes and neutrophil populations in CpG treated animals
would very likely contribute to control of bacterial growth and
protection. Neutrophils have been shown to play critical roles in
resistance to B. pseudomallei infection [29]. They displayed potential
microbicidal capacity by production of reactive oxygen interme-
diates and increased early pro-inflammatory cytokine production.
We detected elevated levels of G-CSF, IL-6, and KC, which
supported enhancement of migration, activation and proliferation
of neutrophils. Our study showed that in the case of a fast
progressing disease, such as melioidosis, the time of activation of
host defense is a very important factor in successful treatment. The
early activation of innate immunity and pro-inflammatory
responses were critical to successful eradication of the pathogen,
whereas elevated cytokine levels at later time points was likely the
result of poorly controlled bacterial growth. Our results are in
agreement with a model of pro-inflammatory responses of innate
immunity proposed by Netea et al., [20]. The authors emphasized
that in acute severe infection, the relative deficiencies in innate
immunity could lead to rapid multiplication of the invading
pathogen with a massive secondary reaction of the host which
could ultimately lead to shock and death.
It has been shown previously that B. pseudomallei infection in
BALB/c mice promoted a strong local inflammatory response, but
an increased level of cytokines and chemokines was not always
effective in reducing the bacterial load [5,24,25]. The responses
did not protect the animals but likely contributed to pathology
through tissue destruction [5,24]. Comprehensive analysis of
cytokine and chemokine profiles after B. pseudomallei infection in
Figure 3. Histological analysis. Representative images from
Hematoxylin and Eosin stained mouse lungs for control (A) and CpG
treated (B) animals at day 3 post infection. At day 3 post infection,
control animals show large nodular, confluent areas of alveolar
inflammation with necrosis, whereas inflammation in CpG treated
animals is sparse, peribronchial and perivascular in location, and
without necrosis.
doi:10.1371/journal.pone.0034176.g003
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ODN administration, but before infection, and 48 h post infection. Cells were labeled with monoclonal antibodies Ly6G/C-PE, CD11c-FITC, CD11b-
PerCpCy5.5, F4/80-APC with corresponding isotype controls and analyzed using FCS Express Version 3. Shown in (A) is the flow cytometric analysis of
leukocytes, side scatter and forward scatter characteristics of isolated cells (Gate 1), gating strategy for analysis of F4/80+ (monocyte/macrophages,
Gate 2) and F4/802 (Gate 3) and CD11c+ (DC, Gate 4) cell populations. Shown are representative plots for numbers of inflammatory monocytes (F4/
80+Ly6G/C+ cells) and neutrophils (F4/802CD11c2CD11b+Ly6G/C+ cells) following CpG treatment and B. pseudomallei infection. Results are
representative of 3 animals per group. Shown in B and C are a summary of monocyte and neutrophil numbers in lung and blood of CpG and non-
treated animals prior to and following infection. Data are presented as mean 6 SEM using one-way ANOVA followed by a Dunnett’s multiple
comparison test for group comparisons (GraphPad Software v4.0). Statistically significant values are designated as follows: *, p,0.05; **, p,0.01.
doi:10.1371/journal.pone.0034176.g004
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chemokines during the early stage of infection in mice treated with
CpG ODN was associated with greater protection against B.
pseudomallei. This is in agreement with previous findings indicating
that protection against acute septicemic melioidosis in BALB/c
mice immunized with CpG ODN type B was associated with a
reduction of bacterial load and moderate production of pro-
inflammatory cytokines [5]. The authors of that study analyzed
cytokine level only in serum after i.p. challenge with B. pseudomallei
strain H1038. The cytokine analysis was limited to a few cytokines
(IFN-c, TNF-a, and IL-12p70) also shown to be very important in
innate host resistance to the closely related bacterium B. mallei [30].
Wongratanacheewin et al., measured the cytokine level in the
animals prior to infection and found small but highly significant
early increases in the level of IL-12p70 and IFN-c, 24 h after CpG
ODN injection [5]. This is a very important finding because these
two cytokines are critical in stimulating activation of macrophages,
NK cells and other innate immunity cells. In mice infected with B.
pseudomallei, NK cells were shown as the principle source of IFN-c
while monocytes were the primary source of TNF-a [29]. Although
our study indicates that a large production of these cytokines was
not necessarily beneficial for either bacterial burden or survival of
the control mice, the time of very early release of these cytokines
seems to be a very important factor contributing to protection.
In a separate study, it was shown that CpG ODN, type B
enhanced phagocytosis of B. pseudomallei and induced nitric oxide
synthase and nitric oxide production by murine macrophages in vitro
[31,32]. Here, we demonstrated that protected CpG pre-treated mice
had a moderate level of IL-12p70 but a much higher level of IL-
12p40. The importance of IL-12 for offering limited protection
against the related pathogen Burkholderia mallei has been shown in
BALB/c mice [33]. Another study of pulmonary B. mallei infection
has shown that recruitment of inflammatory monocytes and DC to
the lungs and local production of IL-12 were important initial
responses required for early protection. [34]. It is possible that upon
early activation of TLR9 by CpG, the resident or recruited antigen
presenting cells are able to produce a greater amount IL-12p40. The
role of p40 is not fully understood, and a recent study presented
evidence that this molecule activates pro-inflammatory responses in
experimental allergic encephalomyelitis [35]. Another potential
e x p l a n a t i o nf o rt h ed i f f e r e n c ei nI L - 1 2e x p r e s s i o nb e t w e e nt h e
groups is negative regulation by IL-6. As IL-12 is negatively regulated
by IL-6 [36], the higher level of IL-6 in the non-treated group may
suppress IL-12 activation following infection in this group.
Histopathological examination of lung sections demonstrated
microabscesses in infected lungs, mimicking human respiratory
melioidosis [37]. Of note, at 24 h and 48 h, neutrophil aggregates
were larger and more numerous in the control animals compared
to the CpG treated animals. As expected, H&E staining of lung
tissue demonstrated large clusters of neutrophils with stronger
signs of inflammation and lesions in control animals. Interestingly,
histological analysis of tissue from patients with melioidosis
presented predominantly neutrophilic lesions at infected sites
[38]. Increased infiltration of neutrophils occurs in many acute
lung diseases and it is part of lung’s defense system but has also
been implicated in pathogenic processes. Despite the fact that we
detected early infiltration of lungs with large number of
inflammatory monocytes and neutrophils in CpG treated animals,
the lung of these animals were cleared from pathogen without
causing extensive lung damage seen in control animals. This
observation suggests that in CpG treated mice, clearance of
apoptotic neutrophils by professional phagocytic cells may be
properly initiated early during infection. A study showing that
CpG ODN enhances ingestion of apoptotic neutrophils by
macrophages in vitro supports this observation [16].
In summary, CpG pretreatment of susceptible BALB/c mice
results in recruitment of neutrophils and monocytes to the lung,
better control of bacterial growth and survival, simultaneously with
an early, moderate, production of pro-inflammatory cytokines and
chemokines. Our study indicates that during infection, a large
production of these cytokines was not necessarily beneficial for
Figure 5. Murine chemokines responses. Level of chemokines in
plasma in pg/ml of control and CpG treated animals during first three
days post-infection (Panels: A- day 1; B- day 2; C- day 3). Plasma from
two mice was analyzed for each time point. Data are presented as mean
6 SEM *p,0.05 ***p,0.001.
doi:10.1371/journal.pone.0034176.g005
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vaccine or effective antibiotic therapies, the beneficial immuno-
modulatory effect of CpG ODN could offer an alternative
prophylactic approach to protect populations at risk of exposure
to the weaponized form of the bacteria.
Methods
Ethics Statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of Laboratory
Animals of the National Institutes of Health. The protocol was
approved by the Animal Care and Use Committee of the University
of Texas Medical Branch (Protocol Number: 0503014A).
Bacterial strain
B. pseudomallei strain K96243 was cultured on Luria-Bertani
supplemented with 4% glycerol (LBG) agar plates for 48 h at
37uC. Isolated colonies were sub-cultured to LBG broth, and
cultures were incubated at 37uC until optical density readings at
600 nm (OD600) reached an exponential phase of growth. Bacteria
were pelleted by centrifugation, washed and re-suspended in sterile
Figure 6. Murine cytokine responses. Level of individual cytokines in plasma (pg/ml) of control and CpG treated animals during the first six days
post-infection. Blood from two mice was analyzed for each time point. Data are presented as mean 6 SEM *p,0.05 ***p,0.001.
doi:10.1371/journal.pone.0034176.g006
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CFU/ml. All procedures were performed in a biosafety level 3
laboratory.
Mice
Female, 8- to 10-week-old, BALB/c mice were obtained from
Harlan Sprague Dawley, Inc. (Indianapolis, Indiana). Animals
were provided with rodent feed and water ad libitum and
maintained on 12 h light cycle. All animal experiments were
performed under animal biohazard containment level 3 condi-
tions.
CpG ODNs administration and B. pseudomallei challenge
Groups of 10 or 20 animals were inoculated via the intranasal
(i.n.) route with dose equal to 2–4 LD50 of B. pseudomallei, strain
K96243 depending on experiments, in a total volume of 50 mli n
PBS solution divided into both nares. The 1 LD50 dose was
established in previous studies as 3.12610
2 for intranasal route in
BALB/c mice. Phosphorothioate-stabilized CpG oligodeoxynu-
cleotides were purchased from Coley Pharmaceutical Group,
Ottawa, Canada. CpG ODN type B 1826 (TCC ATG ACG TTC
CTG ACG TT) or type C 2395 (TCG TCG TTT TCG GCG
CGC GCC G) was administered 48 h prior challenge via i.n.
route, 20 mg per mouse in 50 ml of water into both nares (25 ml
each). The post-challenge administration of CpG ODN, type C
(1 h post-challenge) was also tested. Control animals received
corresponding non-CpG ODN 2138 for type B (TCC ATG AGC
TTC CTG AGC TT) or 2137 for type C (TGC TGC TTT TGT
GCT TTT GTG CTT) respectively in the same amount, route
and time.
Bacterial load determination
Two animals from each group (control, not treated and CpG
treated) were sacrificed on days 1, 2, 3, 6, 13, and at the end of the
study, blood, lungs and spleens were harvested for CFU
determination, cytokines and chemokines analysis or histological
examinations. Organs were weighed, half of each organ was
homogenized in 1 ml sterile PBS, and serial 10-fold dilutions were
plated in duplicates on LBG agar plates and incubated at 37uC for
2 days prior to CFU determinations. The CFUs were expressed as
the mean 6 SEM. Remaining homogenates were spun in a
microcentrifuge and stored frozen for cytokine analysis. Bacterial
load determination was only performed in experiments testing
prophylactic administration of CpG ODN, type C.
Histopathology of the lungs
Two animals from each group (control, not treated and CpG
treated) were sacrificed on days 1, 2, 3, 6, 13, and at the end of the
study. Lungs were instilled with formalin, processed and paraffin-
embedded. Hematoxylin and Eosin stained slides, containing 1–6
sections of lung, were examined by a pathologist (Dr. Aronson) for
lesion number and lesion size. The average number of lesions per
section was determined for each animal. Lesion size was estimated
in relation to the number of alveoli involved. The presence or
Figure 7. Cytokines and chemokines from infected organs. Level of individual cytokines and chemokines (pg/mg tissue) in lungs of control
and CpG treated animals during the first six days post-infection. Two mice were sacrificed from each group at each time point. Lungs were
homogenized in PBS and cytokine and chemokine analysis was performed using Bio-Plex cytokine assay (Panels A and B). Data are presented as mean
6 SEM *p,0.05 ***p,0.001.
doi:10.1371/journal.pone.0034176.g007
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noted.
Cell isolation and flow cytometry
Blood (200 ml) was collected by cardiac puncture and lungs were
harvested from 8-week old female BALB/c mice (Harlan
Laboratories) following sacrifice as approved by the Institutional
Animal Care and Use Committee. Single cell suspensions of lung
tissue were prepared from harvested lungs following tissue
disruption as previously described [39]. Red blood cells (RBC)
in lung and peripheral blood samples were lysed using RBC Lysis
Buffer (Sigma) according to the protocol provided by the
manufacturer. A white blood cell count and analysis of cell
viability was performed by trypan blue exclusion. Samples were
labeled with fluorescent monoclonal antibodies for flow cytometric
analysis, using procedures that we have previously described [40].
The following monoclonal antibodies (mAb) against mouse
antigens were purchased from BD Biosciences: Ly6G/C-PE,
CD11c-FITC, CD11b-PerCpCy5.5, and F4/80-APC. Corre-
sponding isotype controls were also purchased from BD
Biosciences: IgG2b-PE, IgG2b-FITC, IgG2a-APC, or IgG1-
PerCPCy5.5. Cells were then washed and re-suspended in
500 ml of 4% ultrapure formaldehyde (Polysciences Inc.). Samples
were fixed for 48 h, with fresh 4% formaldehyde replacement at
24 h, and sterility confirmed by lack of growth of B. pseudomallei on
selective growth agar plates. A total of 400 ml of sample (blood or
lung suspension) was acquired on a FACS Canto (BD Biosciences,
UTMB Flow Cytometry and Cell Sorting Core Facility) and
compensation for spectral overlap was performed using FACS
DIVA software (BD Biosciences). Isotype- and fluorochrome-
matched non-specific control antibodies were used to determine
background fluorescence. Analysis was performed using FCS
Express version 3 (De Novo Software) as we have previously
described [40]. Data is presented as the number of gated events
corresponding to the expected live leukocyte side scatter and
forward scatter gate. Assessment is based on the number of F4/
80
+Gr1
2 (macrophages), F4/80
+Gr1
+ (inflammatory monocytes),
and F4/80
2CD11c
2CD11b
+Gr1
+ (neutrophils) cells in the live
leukocyte gate. Data are shown as mean 6 SEM. One-way
ANOVA followed by a Dunnett’s multiple comparison test for
group comparisons (GraphPad Software v4.0). Statistically signif-
icant values are designated as follows: *, p,0.05; **, p,0.01.
Measurement of blood, lung and spleen cytokines and
chemokines
Bio-Plex cytokine assays are optimized for the Bio-Plex system,
which uses xMAP detection technology. Multiplex premixed
panels of 23 mouse cytokines/chemokines was detected in mouse
samples (IL-1a, IL-1b, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10,
IL-12 (p40), IL-12 (p70), IL-13, IL-17, EOTAXIN, G-CSF, GM-
CSF, IFN-c, KC, MCP-1, MIP-1a, MIP-1b TNF-a, RANTES). A
detailed cytokine or chemokine analysis was only performed in
experiments testing prophylactic administration of CpG ODN,
type C.
Statistical analysis
Survival curves were calculated by Kaplan Meier survival
analysis with log-rank tests between groups using GraphPad Prism
(v.4.03 for Windows). All other data were analyzed by Student’s t-
test. P value#0.05 was considered significant.
Supporting Information
Figure S1 Cytokines and chemokines from infected
spleens. Level of individual cytokines and chemokines (pg/mg
tissue) in spleens of control and CpG treated animals during the
first six days post-infection. Two mice were sacrificed from each
group at each time point. Spleens were homogenized in PBS and
cytokine and chemokine analysis was performed using Bio-Plex
cytokine assay. Data are presented as mean 6 SEM *p,0.05
***p,0.001.
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